Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01756729 · ClinicalTrials.gov registry record · Phase 4
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Phase 4 study, sponsored by NovoCure.
- Terminated
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT01756729 is a Phase 4 study that was terminated before completion, run by NovoCure. The registered enrollment target is 13 participants.
The verdict
NCT01756729, a Phase 4 study, was terminated before completion, sponsored by NovoCure.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a non-randomized, concurrent control study, designed to confirm that the efficacy of the NovoTTF-100A System in patients with recurrent GBM treated in a real life settings following approval is comparable to that of BSC chemotherapy patients. The device is a portable, battery operated device that was approved for the treatment of adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically- or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.
Interventions
- DEVICE NovoTTF-100A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-12 |
| Est. Completion | 2018-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01756729
The ClinicalTrials.gov registry entry for NCT01756729 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NovoCure, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NovoTTF-100A is the first listed.
NCT01756729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01756729 about?
NCT01756729 is a clinical study titled "Post-approval Study of NovoTTF-100A in Recurrent GBM Patients". This is a non-randomized, concurrent control study, designed to confirm that the efficacy of the NovoTTF-100A System in patients with recurrent GBM treated in a real life settings following approval is comparable to that of BSC chemotherapy patients. The device is a portable, battery operated device...
What is the current status of trial NCT01756729?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2012-12. Estimated completion is 2018-01.
What interventions are being tested in trial NCT01756729?
The interventions under investigation include: NovoTTF-100A (DEVICE).
Who is sponsoring clinical trial NCT01756729?
This trial is sponsored by NovoCure, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.